Randomized Trial on Same-day SBRT and Surgical Stabilization for Symptomatic Spinal Metastases
BLEND
Stereotactic Body Radiotherapy and pedicLE Screw fixatioN During One Hospital Visit for Patients With Painful Unstable Spinal Metastases: A Randomized Trial (BLEND)
1 other identifier
interventional
100
1 country
1
Brief Summary
The BLEND RCT aims to evaluate the (cost-)effectiveness of same-day SBRT and surgical stabilization with or without decompression for the treatment of symptomatic, unstable spinal metastases on physical functioning four weeks after the start of treatment, compared with the standard of care (surgery followed by radiotherapy as soon as the wound healed sufficiently).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Oct 2022
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 29, 2022
CompletedFirst Posted
Study publicly available on registry
October 12, 2022
CompletedStudy Start
First participant enrolled
October 15, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2027
April 3, 2025
March 1, 2025
3.7 years
September 29, 2022
March 31, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Physical functioning
Physical functioning is a functional scale from the EORTC QLQ-C15-PAL questionnaire. Patients rate each item on a 4-point Likert scale ranging from 1 (not at all) to 4 (very much), and scale scores were linearly transformed to a 0-100 scale. A higher score on the functional scale indicates better functioning.
at 4 weeks after the start of treatment
Secondary Outcomes (11)
Pain response
at 2, 4, 6 and 8 weeks, and 3 months after the start of treatment
Duration of pain relief
up to 3 months
Duration of hospital stay
up to 3 months
Days until return to systemic treatment
up to 12 months
Neurological deterioration
up to 12 months
- +6 more secondary outcomes
Other Outcomes (1)
Cost-effectiveness
up to 12 months
Study Arms (2)
Intervention
EXPERIMENTALPatients will receive high dose, single fraction stereotactic body radiotherapy (SBRT) using differential dosing: 18 or 21 Gy on the metastasis. Within 24 hours after SBRT, patients will have surgical stabilization with or without decompression.
Control
ACTIVE COMPARATORPatients will undergo the standard of care, which is surgical stabilization with or without decompression, followed by conventional radiotherapy (cRT) or SBRT as soon as the wound is healed sufficiently.
Interventions
SBRT and surgical stabilization with or without decompression within 24 hours
Surgical stabilization with or without decompression followed by cRT or SBRT as soon as the wound is healed sufficiently
Eligibility Criteria
You may qualify if:
- Symptomatic (cervical, thoracic and/or lumbar) spinal metastases from solid tumors and (impending) spinal instability requiring radiotherapy and surgical decompression and/or stabilization
- Histologic proof of malignancy or radiographic/clinical characteristics indicating malignancy beyond reasonable doubt
- Radiographic evidence of spinal metastases
- Participation in PRESENT cohort, including consent for randomization into future trials
- Fit for (radio)surgery
- Age \>18 years
- Written informed consent
You may not qualify if:
- SBRT cannot be delivered, e.g. in patients who cannot lie on the treatment table because of pain
- Routine surgical decompression and/or stabilization and radiotherapy cannot be performed, e.g., multiple spinal metastases requiring surgical bridging of more than five vertebral levels and/or requiring radiotherapy on more than one location
- Prior surgery or radiotherapy to the index level(s)
- Multiple myeloma
- Neurological deficits (ASIA C, B or A), or partial neurological deficits (ASIA D) with rapid progression (hours to days)
- Treated with Bevacizumab and other medication with long half-life that interferes with radiotherapy
- Life expectancy of less than 3 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- UMC Utrechtlead
- Radboud University Medical Centercollaborator
Study Sites (1)
University Medical Center Utrecht
Utrecht, Netherlands
Related Publications (1)
Huele EH, van der Velden JM, Kasperts N, Eppinga WSC, Grutters JPC, Suelmann BBM, Weening AA, Delawi D, Teunissen SCCM, Verkooijen HM, Verlaan JJ, Gal R. Stereotactic Body radiotherapy and pedicLE screw fixatioN During one hospital visit for patients with symptomatic unstable spinal metastases: a randomized trial (BLEND RCT) using the Trials within Cohorts (TwiCs) design. Trials. 2023 May 4;24(1):307. doi: 10.1186/s13063-023-07315-y.
PMID: 37143158DERIVED
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Helena M. Verkooijen, Prof
UMC Utrecht
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Masking Details
- According to the TwiCs design, patients allocated to the control group are not informed about their role as a control in the trial.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof. H.M. Verkooijen
Study Record Dates
First Submitted
September 29, 2022
First Posted
October 12, 2022
Study Start
October 15, 2022
Primary Completion (Estimated)
June 30, 2026
Study Completion (Estimated)
June 30, 2027
Last Updated
April 3, 2025
Record last verified: 2025-03